Showing 501-510 of 9757 results for "".
Clinical Questions About Isotretinoin and More
https://practicaldermatology.com/conferences/maui-derm-hawaii-2026/clinical-questions-about-isotretinoin-and-more/54661/Lawrence Eichenfield, MD, discusses key takeaways from the “Acne and Rosacea: Update 2026” session at Maui Derm Hawaii 2026.DermwireTV: Rinvoq Approved for Pediatric Psoriatic Arthritis; J&J Acquires Novel AD Candidate
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-rinvoq-approved-for-pediatric-psoriatic-arthritis/26269/In this week's DermwireTV, the FDA approves Rinvoq for pediatric psoriatic arthritis; Johnson & Johnson acquires an AD candidate for $1.25 billion; and the president of Acclaro Medical discusses the latest FDA clearance of its Ultraclear Laser.Hilary Baldwin, MD: Perspective on the FDA Citizen's Petition for Acne Products with Benzoyl Peroxide (BPO)
https://practicaldermatology.com/topics/acne-rosacea/hilary-baldwin-md-perspective-fda-citizens-petition-acne-products-benzoyl-peroxide-bpo/24171/Neal Bhatia, MD, chief medical editor of Practical Dermatology® talks to Hilary E. Baldwin, MD about a new report from an independent laboratory that finds benzene can form at unacceptably high levels in both over-the-counter and prescription medications that contain benzoyl peroxide.DermWireTV: Cutera, Galderma Acne Treatments; Alma's TED; Diversity Initiatives
https://practicaldermatology.com/topics/practice-management/dermwiretv-cutera-galderma-acne-treatments-almas-ted-diversity-initiatives/20084/There are two new options for treating acne. Cutera introduces the AviClear acne device; Galderma launches Twyneo Cream. Joshua Zeichner, MD weighs in. Lady Dy, MD discusses Alma’s TED device, a non-invasive, non-traumatic option to address hair loss. New initiatives announced at or in conjunction wDermWireTV: Updates from ASDS: EBDs, Injectables, Scars, DEI
https://practicaldermatology.com/topics/practice-management/dermwiretv-updates-from-asds-ebds-injectables-scars-dei/20029/The annual meeting of the American Society for Dermatology Surgery (ASDS) brings together top dermatologists to share their expertise. This year’s virtual meeting offered a look at a range of new and emerging treatments and some updates on existing options, including insights from Jeanine B. Downie,DermWireTV: Soliton's Resonic Launch, Natroba for Scabies, UV Safety
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-solitons-resonic-launch-natroba-for-scabies-uv-safety/19938/Skin Cancer awareness month provides an opportunity for dermatologists to double down on patient outreach as the AAD launches the “Skin Cancer, Take a Hike” steps challenge. Soliton’s Rapid Acoustic Pulse Device launches under the name Resonic. Natroba (Spinosad) Topical Suspension from ParaPRO is nILUMYA SUPPORT™ patient access for commercial and Medicare Part B patients
https://practicaldermatology.com/topics/psoriasis/ilumya-support-patient-access-for-commercial-and-medicare-part-b-patients/19860/ILUMYA SUPPORT™ offers comprehensive programs and services to help patients start and stay on therapy with ILUMYA™. Learn about the three main patient access programs offered by ILUMYA SUPPORT™: the Early Access Program, the Co-pay Program, and the Patient Assistance Program. ILUMYA™ is reimbursed uFDA Approvals, Acne Insights, EPI Gets Cloderm
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-fda-approvals-acne-insights-epi-gets-cloderm/18230/In a flurry of approvals, FDA gives the nod to Almirall's Seysara (sarecycline), Ortho Dermatologics' Bryhali (halobetasol propionate, 0.01%) Lotion, Paratek Pharmaceuticals' Nuzyra (omadacycline), and Regeneron's Libtayo (cemiplimab). Research shows top earners across various fields in the US mayAltreno's Approval, Psoriasis Insights
https://practicaldermatology.com/topics/psoriasis/dermwire-tv-altreno-s-approval-psoriasis-insights--nxhineya/18236/Ortho Dermatologics' Altreno lotion is now approved for the topical treatment of acne vulgaris in patients ages 9 and up. Altreno, containing tretinoin 0.05%, will be available during the fourth quarter of this year. The FDA has accepted Ortho Dermatologics' resubmitted New Drug Application for DuobSummer AAD NYC Updates; Modernizing Medicine Grows
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-summer-aad-nyc-updates-modernizing-medicine-grows-/18444/As in years past, the summer meeting of the AAD has focused attention on optimal uses for both existing and emerging therapies in the dermatology clinic, including, PRP. Dr. Nicole Rogers assessed the role of PRP for hair loss. Diane Berson, MD discusses acne, Adam Friedman, MD addresses the microbi